Disc Medicine says DISC-0974 posts durable anemia responses in Phase 2 RALLY-MF trial in myelofibrosis

Disc Medicine, Inc.

Disc Medicine, Inc.

IRON

0.00
  • Disc Medicine disclosed updated Phase 2 results presented at the 2026 EHA meeting for DISC-0974 in myelofibrosis-related anemia.
  • Patients showed durable improvement in anemia outcomes across key subgroups, including those on JAK inhibitors or with baseline transfusion needs.
  • Safety looked generally acceptable, with treatment-related side effects described as limited.
  • Updated Phase 2 extension data for bitopertin in erythropoietic protoporphyria will be presented June 13, showing sustained clinical benefit with supportive longer-term safety.
  • Bitopertin’s Phase 3 APOLLO readout remains slated for Q4 2026, positioned as the next decision point for a potential resubmission path.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120830PRIMZONEFULLFEED9745742) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.